Fermer le menu



From October 10th and 11th, the fourth edition of Innovative therapies days – ITD will be held in Besançon (25), France.



Innovative Therapies Days is the key symposium that will give a large part to exchanges between experts in their field: 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬, 𝐜𝐥𝐢𝐧𝐢𝐜𝐢𝐚𝐧𝐬, 𝐚𝐧𝐝 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬. You will find them through an 𝐄𝐱𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐕𝐢𝐥𝐥𝐚𝐠𝐞, 𝐁𝟐𝐁 𝐬𝐞𝐬𝐬𝐢𝐨𝐧𝐬, 𝐚𝐧𝐝 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐭𝐢𝐦𝐞𝐬 and discover their latest scientific progress on CAR-T cells, cell therapies, and cell-derived innovative therapies. While the Bourgogne-Franche-Comté region is the birthplace of microtechnology, it is the combination of those technologies with cell therapies that enabled the RIGHT institute to bring out flagship products like CAR-T cells! With some national partners and international partners and around 600 visitors, ITD brings together 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬, 𝐜𝐥𝐢𝐧𝐢𝐜𝐢𝐚𝐧𝐬, 𝐚𝐧𝐝 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐢𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 for 2 days of high-level conferences about CAR-T cells, cell therapies, cell-derived innovative therapies and regulation, production, and clinical transfer of innovative therapies.




Among recent medical innovations, CAR-T cells have revolutionized the treatment of patients with refractory or relapsed hematological malignancies, and their chances of recovery, in both adults and children. Despite their clinical significance, there are limitations to producing and employing CAR-T therapies. We invite experts in the field to present new data, innovative or complementary approaches to this burning issue.




Cell therapy is a promising, rapidly advancing field with the potential to transform medicine across disease areas where significant need exists. Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization. Presentations of cell (modified or not) therapies will be given to explore this extensive topic, which covers many therapeutic areas.




Cell therapies are difficult to transport and administer. In some cases, trials have shown that the use of extracellular vesicles (EV) or the secretome can produce equally interesting effects, without the constraints of cellular therapies. EVs and secretome, the global study of molecules that are secreted by a cell, are an emerging source of new therapeutic products. After an outstanding first session in 2023, the subject will be back in the spotlight in 2024.




Adhérents de Lyonbipôle, profitez d’un code de réduction.
Connectez-vous à votre espace adhérent ci-dessous.


Le contenu de cette page est réservé à nos membres.

Vous êtes membre de Lyonbiopôle ?

Veuillez vous identifier pour accéder au contenu qui vous est réservé.

Mot de passe oublié

Vous n'êtes pas membre de Lyonbiopôle

Adhérer à notre pôle de compétitivité vous procure de nombreux avantages. Cela vous permet par exemple d'avoir accès à nos contenus premium, comme dans le cas présent.